Janelle Hart

Lead author David M. Schuster, MD, FACR, assessed the detection rate of the novel theranostic PET ligand in a population of almost 400 men and found that the data supported clinical utility of 18F-rhPSMA-7.3 PET in managing men with recurrent prostate cancer across a wide range of prostate-specific antigen levels.

A recent trial investigated the prognostic value of the 22-gene Decipher genomic classifier in patients with intermediate-risk prostate cancer.

Hong Truong, MD, served as a co-investigator of a recent study that defined selection criteria for patients with upper tract urothelial cancer for Lynch syndrome screening.

Investigators of a recent study presented at the 2022 ASCO Genitourinary Cancers Symposium reported favorable outcomes of pembrolizumab in patients with renal cell carcinoma at 30-month follow up.

In this interview, lead author Benjamin Lowentritt, MD, FACS, discusses why the findings of the study, "Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide," are so important in future counseling for mCSPC.

Five women urologists in sexual medicine share their experiences in providing care.

A study presented at the 2022 ASCO Genitourinary Cancers Symposium investigated how MTAP deletion is a potentially actionable mutation for developing novel therapies for genitourinary cancers.

A recent study suggests that patients with adrenocortical carcinoma at low-intermediate risk of recurrence do not derive significant benefit from postoperative adjuvant mitotane treatment.

“There’s excellent image quality,” said David M. Schuster, MD, “and also the potential for low urinary secretion, which, as we know, is important for imaging prostate cancer.”

In this interview, Alexandra Rogers, MD, discusses how urologists can help patients with OAB feel normal.

Shawn Dason, MD, discusses the findings and takeaways of the study, "How often does cisplatin ineligibility prevent patients from receiving adjuvant therapy following radical nephroureterectomy for upper tract urothelial carcinoma?"

A recent study published in Radiotherapy & Oncology, investigates the potential for germline variants to predict long-term toxicity in patient who have received radiation.

Gregory Tasian, MD, MSc, MSCE, and Jason Kaufman co-authored a study that investigated the association between kidney stone presentations in South Carolina under 2 different climate change scenarios.

In this interview, Polina X. Reyblat, MD, discusses the ways in which urologists can make their practices a more comfortable and open environment for patients of all different backgrounds to receive care.

"Open ureteral reimplantation for ureteral obstruction in ileal-conduit has excellent early outcomes, though a 1/3 experienced high grade complications during follow up," wrote the study's authors, led by Zhina Sadeghi, MD, of the University of Michigan in Ann Arbor.

At 3 months, 83% of patients (5/6) who received EG-70 achieved complete response, according to the treatment manufacturer, enGene.

Jerry G. Blaivas, MD, FACS, debunks some of the common stigmas associated with mesh slings.

To destigmatize testosterone deficiency, Justin Dubin, MD, advises clinicians on how to create a comfortable space for their patients and advises patients on how to be comfortable with talking about their deficiency.

“We have to be more mindful and thoughtful about the fact that certain populations are underrepresented in clinical trials, and that’s likely due to a number of factors,” said co-author Padraic O’Malley, MD, MSc, FRCSC.

“Patients are overwhelmed by these choices often, and don't really understand the risks and benefits when they're first told about them,” said co-author Anjali Kapur, MD.

A recent study presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference investigated the quality of information regarding urinary tract infections on the social media platform Reddit.

“Inappropriate patient interactions are more prevalent than we know, and they're oftentimes underreported,” said Caroline Lu, MD

To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.

“Previous OAB studies could be inadvertently excluding large populations of patients due to language barriers, access to academic centers, collecting research data, or differences in beliefs in health care in general,” said co-author Beth Edelblute, MD, MPH.

Priya Padmanabhan, MD, MPH, shares the main takeaways from her discussion, “Advocacy and Health Policy Update: The Politics of Policy,” which she presented during the 2022 Society of Women in Urology Annual Clinical Mentoring Conference.

Anne M. Suskind, MD, highlights her presentation, “Mentorship as a Team Sport,” from the 2022 Society of Women in Urology Annual Clinical Mentoring Conference.

To analyze real-world data of urinary incontinence, Heidi Wendell Brown, MD, MAS, FACOG, Ushma J. Patel, MD, and co-authors conducted a study involving the 2015-2018 National Health and Nutrition Examination Survey (NHANES).

In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.

“[MIPS represents] a significant paradigm shift away from the traditional fee-for-service model and toward the concept of value-based care," wrote Ridwan Alam, MD, MPH, and coauthors.

In a recent interview, Philippe E. Spiess, MD, and Andrea Necchi, MD, shared how they aim to develop an environment that emphasizes education, patient advocacy, and clinical research for rare genitourinary cancers.